Taking positive cues from Nifty healthcare index, domestic pharma stocks outperformed all other sectoral stocks on Friday, with shares of Cipla leading the pack.
Indian vaccine maker Bharat Biotech said on Friday the Russia-Ukraine conflict had not impacted the company's supply chains so far. Unlike several Western companies including McDonald's, Microsoft, Coca-Cola and Starbucks that have stopped sales or
As the healthcare industry across the globe has started focusing increasingly on outcomes, pharma companies are looking to sources beyond Randomized Clinical Trials (RCTs) to measure and demonstrate the value they bring.
Pharmaceutical major Dr. Reddy's Laboratories Ltd said it is focused on employee safety and business continuity in and around Russia, despite many Western companies pulling out from Russia in recent days. No Indian company has publicly withdrawn from
Indian pharmaceutical major Dr. Reddy's Laboratories Ltd said it is focused on business continuity in and around Russia, as Indian drug exporters’ brace for temporary disruptions to sales due to the Ukraine crisis. No Indian company has publicly wit.
Christian Medical College (CMC) Vellore will soon share preliminary results of a study to test the feasibility of mixing Covishield and Covaxin - the two main Covid-19 vaccines available in the country - with the country's drug regulator, a senior of
Natco Pharma along with its marketing partner Arrow International - an affiliate of Israeli-drug maler Teva Pharmaceutical Industries announced the launch of the first generic version of Celgene's (now acquired by Bristol Myers Squibb) top selling ca
Six pharmaceutical majors Aurobindo, Biocon, Dr Reddy's, JB Chemicals, Torrent Pharma and Zydus Healthcare have been shortlisted for the acquisition of Curatio Healthcare, the Chennai-based company focused on skincare products, multiple people aware
India's pharmaceuticals market (IPM) is expected to grow between 6 and 8 per cent on a year-on-year (YoY) basis in FY23. India's pharmaceuticals market (IPM) is expected to grow between 6 and 8 per cent on a year-on-year (YoY) basis in FY23.India's
The Subject Expert Committee (SEC) under the Central Drugs Control Standard Organisation on Friday recommended Serum Institute of India's (SII) Covid-19 vaccine, Covovax, for emergency use authorisation in the 12-17 age group, people in the know told
, CDSCO.jpg)
